Sporadic and neurofibromatosis 2-related vestibular schwannomas overexpress c-kit and PDGFR, which are targets of the receptor tyrosine kinase (RTK) inhibitor imatinib. This evidence concerns the gene KIT and Vestibular schwannoma.